Plasma free metanephrine and normetanephrine levels are increased in patients with chronic kidney disease

Endocrine Practice

Volumn 20, Issue 2, 2014, Pages 139-144

  Niculescu, Dan A ^a   Ismail, Gener ^a   Poiana, Catalina ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

METADRENALIN; NORMETADRENALIN;

ADULT; AGED; BLOOD; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; FEMALE; HUMANS; MALE; METANEPHRINE; MIDDLE AGED; NORMETANEPHRINE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84894131390     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13251.OR     Document Type: Article

References (22)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
2. Saeki T, Suzuki K, Yamazaki H, et al. Four cases of pheochromocytoma in patients with end-stage renal disease. Intern Med. 2003;42:1011-1015.
3. Stumvoll M, Radjaipour M, Seif F. Diagnostic considerations in pheochromocytoma and chronic hemodialysis: case report and review of the literature. Am J Nephrol. 1995;15:147-151.
4. Gorsane I, Zouaghi K, Goucha R, et al. Pheochromocytoma in end-stage renal disease patient treated by peritoneal dialysis. Nephrol Ther 2008;4:597-601.
5. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004;65:1568-1576.
6. Ziegler MG, Kennedy B, Morrissey E, O'Connor DT. Norepinephrine clearance, chromogranin A and dopamine beta hydroxylase in renal failure. Kidney Int. 1990;37:1357-1362.
7. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287:1427-1434.
8. Procopiou M, Finney H, Akker SA, et al. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors. Eur J Endocrinol. 2009;161:131-140.
9. Gao YC, Lu HK, Luo QY, Chen LB, Ding Y, Zhu RS. Comparison of free plasma metanephrines enzyme immunoassay with (131) I-MIBG scan in diagnosis of pheochromocytoma. Clin Exp Med. 2008;8:87-91.
10. Unger N, Pitt C, Schmidt IL, et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol. 2006;154:409-417.
11. Mullins F, O'Shea P, FitzGerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med. 2011;50:105-110.
12. Eisenhofer G, Huysmans F, Pacak K, Walther MM, Sweep FC, Lenders JW. Plasma metanephrines in renal failure. Kidney Int. 2005;67:668-677.
13. Hickman PE, Leong M, Chang J, Wilson SR, McWhinney B. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma. Pathology. 2009;41:173-177.
14. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
15. Eisenhofer G, Rundquist B, Aneman A, et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab. 1995;80:3009-3017.
16. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001;91:35-62.
17. McIntyre CW. Hemodynamic effects of peritoneal dialysis. Perit Dial Int. 2011;31 Suppl 2:S73-S76.
18. Kennedy B, Bigby TD, Ziegler MG. Nonadrenal epinephrine-forming enzymes in humans. Characteristics, distribution, regulation, and relationship to epinephrine levels. J Clin Invest. 1995;95:2896-2902.
19. N'Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int. 2002;61:1859-1866.
20. Himmelfarb J, Holbrook D, McMonagle E, Robinson R, Nye L, Spratt D. Kt/V, nutritional parameters, serum cortisol, and insulin growth factor-1 levels and patient outcome in hemodialysis. Am J Kidney Dis. 1994;24:473-479.
21. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: How to distinguish true-from false-positive test results. J Clin Endocrinol Metab. 2003;88:2656-2666.
22. Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. Clin Chem. 2012;58:941-943.